Dual-Modal Therapeutic Role of the Lactate Oxidase-Embedded Hierarchical Porous Zeolitic Imidazolate Framework as a Nanocatalyst for Effective Tumor Suppression
Source abstract
Abstract
The increasing evidence supports the fact that lactate in the tumor microenvironment (TME) plays a vital role in tumor proliferation, metastasis, and recurrence, which in turn is emerging as one of the most interesting molecular targets for tumor treatment. Here, hierarchical porous zeolitic imidazolate framework-8 (ZIF-8) as the nanocarrier is fabricated to simultaneously load lactate oxidase (LOD) and Fe3O4 nanoparticles (NPs), called LOD & Fe3O4@ZIF-8 NPs (LFZ NPs), for tumor therapy. On one hand, the sharp consumption of lactate in the TME by LOD will change the essential “soil” where tumor cells live so as to suppress tumor rapid growth. On the other hand, hydrogen peroxide (H2O2) is produced in the TME from the oxidation of lactate catalyzed by LOD and subsequently converted to highly toxic hydroxyl radicals (•OH) catalyzed by Fe3O4 NPs via Fenton-like reactions to kill tumor cells. Based on the endogenous catalysis, this dual-modal strategy of tumor therapy based on lactate is simple, safe, and effective, which deserves to be well concerned.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biomaterials, College of Materials, Xiamen University, Xiamen, Fujian 361005, P. R. China
Department of Electronic Science, Fujian Provincial Key Laboratory of Plasma and Magnetic Resonance Research, School of Electronic Science and Engineering, Xiamen University, Xiamen, Fujian 361005, P. R. China
Harvard College, Harvard University, 209 Dunster Mail Center, 945 Memorial Drive, Cambridge, Massachusetts 02138, United States
State Key Laboratory of Trauma Burns and Combined Injury, Institute of Combined Injury, Chongqing Engineering Research Center for Nanomedicine, College of Preventive Medicine, Third Military Medical University, Chongqing 400038, P. R. China
Funding
Third Military Medical University · China Scholarship Council · National Natural Science Foundation of China
References (57)
Show source-provided references
1. 10.1016/j.carbpol.2019.11528110.1016/j.carbpol.2019.115281 ↗
2. 10.1016/j.dyepig.2019.10794010.1016/j.dyepig.2019.107940 ↗
3. 10.1002/anie.20190972910.1002/anie.201909729 ↗
4. 10.1021/acsami.9b1495810.1021/acsami.9b14958 ↗
5. 10.1002/adma.20160211110.1002/adma.201602111 ↗
6. 10.1016/j.cmet.2016.08.01110.1016/j.cmet.2016.08.011 ↗
7. 10.1016/j.nantod.2018.06.00810.1016/j.nantod.2018.06.008 ↗
8. 10.1039/c6cs00592f10.1039/c6cs00592f ↗
9. 10.1002/adma.20190288510.1002/adma.201902885 ↗
10. 10.1016/j.addr.2019.06.00710.1016/j.addr.2019.06.007 ↗
11. 10.1016/j.canlet.2019.11.01810.1016/j.canlet.2019.11.018 ↗
12. 10.1038/nrclinonc.2015.20910.1038/nrclinonc.2015.209 ↗
13. 10.1016/j.addr.2018.05.00810.1016/j.addr.2018.05.008 ↗
14. 10.1002/jcp.2742510.1002/jcp.27425 ↗
15. 10.1021/acsami.6b0538310.1021/acsami.6b05383 ↗
16. 10.1021/acsami.7b0308710.1021/acsami.7b03087 ↗
17. 10.1039/c7nr08535d10.1039/c7nr08535d ↗
18. 10.1002/adma.20190158610.1002/adma.201901586 ↗
19. 10.1002/adma.20190749010.1002/adma.201907490 ↗
20. 10.1002/advs.20190324310.1002/advs.201903243 ↗
21. 10.1016/j.jconrel.2019.03.00510.1016/j.jconrel.2019.03.005 ↗
22. 10.1158/0008-5472.can-18-372610.1158/0008-5472.can-18-3726 ↗
23. 10.1126/science.aau986110.1126/science.aau9861 ↗
24. 10.1038/nrc206710.1038/nrc2067 ↗
25. 10.1021/acs.nanolett.8b0429610.1021/acs.nanolett.8b04296 ↗
26. 10.1021/acs.chemmater.9b0050710.1021/acs.chemmater.9b00507 ↗
27. 10.1038/s41467-017-00424-810.1038/s41467-017-00424-8 ↗
28. 10.1021/acs.nanolett.9b0225310.1021/acs.nanolett.9b02253 ↗
29. 10.1016/j.biomaterials.2019.11956810.1016/j.biomaterials.2019.119568 ↗
30. 10.1002/adma.20190527110.1002/adma.201905271 ↗
31. 10.1039/c7cs00471k10.1039/c7cs00471k ↗
32. 10.1021/acs.chemrev.8b0062610.1021/acs.chemrev.8b00626 ↗
33. 10.1002/adma.20190177810.1002/adma.201901778 ↗
34. 10.1073/pnas.131193911010.1073/pnas.1311939110 ↗
35. 10.1073/pnas.091443310710.1073/pnas.0914433107 ↗
36. 10.1158/0008-5472.can-10-282810.1158/0008-5472.can-10-2828 ↗
37. 10.1158/0008-5472.can-18-160410.1158/0008-5472.can-18-1604 ↗
38. 10.1016/j.cell.2019.05.00310.1016/j.cell.2019.05.003 ↗
39. 10.1172/jci6974110.1172/jci69741 ↗
40. 10.1038/nature2405710.1038/nature24057 ↗
41. 10.1016/j.semradonc.2004.04.00810.1016/j.semradonc.2004.04.008 ↗
42. Walenta S. · Cancer Res. · 2000 · 60 · 916
43. 10.1016/j.semradonc.2004.04.00410.1016/j.semradonc.2004.04.004 ↗
44. 10.1038/s41598-017-08277-310.1038/s41598-017-08277-3 ↗
45. 10.18632/oncotarget.974610.18632/oncotarget.9746 ↗
46. 10.1038/srep0492710.1038/srep04927 ↗
47. 10.1002/adma.20190463910.1002/adma.201904639 ↗
48. 10.1002/smll.20190374610.1002/smll.201903746 ↗
49. 10.1039/c8cs00688a10.1039/c8cs00688a ↗
50. 10.1021/acs.accounts.8b0052110.1021/acs.accounts.8b00521 ↗
51. 10.1039/c6sc01359g10.1039/c6sc01359g ↗
52. 10.1021/jacs.6b1207410.1021/jacs.6b12074 ↗
53. 10.1038/nchem.127210.1038/nchem.1272 ↗
54. 10.1002/advs.20180173310.1002/advs.201801733 ↗
55. 10.1002/adma.20190715210.1002/adma.201907152 ↗
56. 10.1021/acsami.9b1129110.1021/acsami.9b11291 ↗
57. 10.1002/anie.20180566410.1002/anie.201805664 ↗